12:00 AM
 | 
Aug 08, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Levadex regulatory update

FDA accepted for review an NDA from Map Pharmaceuticals for Levadex for the acute treatment of migraines. The PDUFA date is March 26, 2012. The acceptance triggers a $20 million payment to Map...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >